AGER, His, Human
AGER, His, Human

The purity of AGER, His, Human is greater than 95% as determined by SEC-HPLC.

AGER, His, Human

AGER, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

AGER, His, Human

The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.
Z04999
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
AGER (Ala23-Ala344)
Accession # Q15109-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 35.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • AGER, His, Human
    • AGER, His, Human

    The purity of AGER, His, Human is greater than 95% as determined by SEC-HPLC.

  • AGER, His, Human
    • AGER, His, Human

    AGER, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.
Synonyms AGER; RAGE; SCARJ1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.